Strategic Funding Mevo has recently secured substantial Series B funding totaling around $19-20 million in 2024 from Matrix Partners and Prosus Ventures, signaling strong investor validation and potential for rapid scale. This suggests a collaborative sales window with healthcare institutions and tech partners looking to align with a well-funded growth trajectory.

Digital Health Expansion The company offers a digital prescription platform and online pharmacy with extensive hospital and clinic partnerships, pointing to opportunities to upsell integrations with existing EMR/EHR systems, digital health records optimization, and expanded telehealth services for clinics seeking end-to-end digital workflows.

Operational Reach With over 900 hospital and clinic partners and emphasis on fast home delivery, there is potential to propose logistics optimization, last‑mile pharmacy delivery enhancements, or nationwide expansion collaborations to reduce patient friction and improve prescription fulfillment times.

Technology Stack Mevo already utilizes Analytics, ELK stack, Pipedrive CRM, GA4, and tag management, indicating openness to data-driven partnerships, custom analytics, and integration projects. Propose analytics dashboards, performance marketing collaborations, and partner-specific data insights to drive adoption and retention.

Commercial Partnerships As a multi-entity group with Mevo Receita Digital and Mevo Farma, there are cross-sell opportunities for loyalty programs, subscription models, and bundled health services serving both prescribers and patients, enabling strategic alliances with insurers, employers, and retail partners.